This event has already occured.
Personalized Cancer Medicine: Are We There Yet?
- When December 6, 2012, 5:30 p.m. to 6:30 p.m.
- Who Eileen Dolan, PhD, Professor of Medicine, Section of Hematology/Oncology; Co-Director, Clinical and Experimental Therapeutics Program of the Comprehensive Cancer Center, University of Chicago, Illinois
- Where Virginia Tech Carilion Research Institute, 2 Riverside Circle, Roanoke
2 Riverside Circle, Roanoke, VA 24016
A primary aim of pharmacogenomics is to devise personalized treatment strategies based on an individual’s genetic makeup to maximize the potential for therapeutic benefit and minimize the risk of adverse side effects. Dr. Dolan will discuss the role of pharmacogenomics in cancer research, a field in which personalized drug therapy is especially desirable given the narrow therapeutic index and life-threatening consequences of drug toxicity.
A public reception will precede this event in the VTC Cafe at 5:00 p.m.
Eileen Dolan, PhD
Eileen Dolan, PhD, is a professor in the Section of Hematology/Oncology in the University of Chicago’s Department of Medicine. She also chairs the Committee on Clinical Pharmacology and Pharmacogenomics, which trains graduate students in subjects ranging from personalized medicine to the genetics of drug abuse. Her laboratory seeks to identify genetic determinants contributing to cellular susceptibility to chemotherapeutic agents. It was the first to demonstrate that susceptibility to chemotherapy-induced cytotoxicity is significantly heritable. Dr. Dolan earned her bachelor’s in chemistry from the University of Dayton and her doctorate in medicinal chemistry from Purdue University.